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Abstract
Interleukin 4 (IL-4) was shown to be tumor-promoting in full carcinogenesis
studies using 3-methylcholanthrene (MCA). Because heretofore the role of IL-4
in DMBA/TPA (9,10-dimethyl-1,2-benz-anthracene/12-O-tetradecanoylphorbol-
13-acetate) two-stage carcinogenesis was not studied, we performed such experi-
ments using either IL-4/ or IL-4Ra/ mice. We found that IL-4Ra/ but
not IL-4/ mice have enhanced papilloma formation, suggesting that IL-13 may
be involved. Indeed, IL-13/ mice developed more papillomas after exposure to
DMBA/TPA than their heterozygous IL-13-competent littermate controls. How-
ever, when tested in a full carcinogenesis experiment, exposure of mice to 25 lg
of MCA, both IL-13/ and IL-13+/ mice led to the same incidence of tumors.
While IL-4 enhances MCA carcinogenesis, it does not play a measurable role in
our DMBA/TPA carcinogenesis experiments. Conversely, IL-13 does not affect
MCA carcinogenesis but protects mice from DMBA/TPA carcinogenesis. One
possible explanation is that IL-4 and IL-13, although they share a common
IL-4Ra chain, regulate signaling in target cells differently by employing distinct
JAK/STAT-mediated signaling pathways downstream of IL-13 or IL-4 receptor
complexes, resulting in different inflammatory transcriptional programs. Taken
together, our results indicate that the course of DMBA/TPA- and MCA-induced
carcinogenesis is affected differently by IL-4 versus IL-13-mediated inflammatory
cascades.
Introduction
The first experimental carcinogenesis protocols were estab-
lished a century ago by Yamagiva and Ichikawa [1], who
painted coal tar on rabbit ears. Subsequent skin carcino-
genesis studies showed that tumor development after a
single sub-tumorigenic dose of a mutagen can be induced
and enhanced by a tumor promoter, such as croton oil,
that is not tumorigenic by itself [2]. While the mutagen/
carcinogen interacts with the DNA to cause mutations, the
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tumor promoter is thought to cause epigenetic changes in
the mutated cells either directly or indirectly via the micro-
environment. Various polycyclic aromatic hydrocarbon
compounds can be used to initiate mutations for the
induction of skin cancer (e.g., 9,10-dimethyl-1,2-benz-
anthracene/DMBA, benzopyrene/BaP, methylcholantrene/
MCA). Other compounds can be used to enhance/promote
tumor formation (e.g., croton oil, 12-O-tetradecanoyl-
phorbol-13-acetate/TPA, or okadaic acid). To date, one of
the most frequently used two-step skin carcinogenesis
models involves application of the carcinogen DMBA fol-
lowed by repeated applications of the tumor promoter
TPA [3, 4]. Skin carcinogenesis studies helped to establish
paradigms of initiation, promotion, and progression of
cancer. Various factors affecting chemical skin carcinogen-
esis have been described, such as wounding [5], diet [6, 7],
composition of skin surface lipids [8], glucocorticoid levels
[9], and genetic background [4, 10]. Because tumor pro-
moters, such as TPA, cause a local inflammatory response,
it is not surprising that immune cells and inflammatory
processes can influence skin carcinogenesis. For example,
experiments in mice lacking ab-T cells or cd-T cells sug-
gested that ab-T cells are tumor-promoting [11–14], while
cd-T cells appeared to be protective [11]. The tumor-
promoting subset of ab-T cells seems to vary depending
on the genetic background. While in the FVB (an inbred
strain of mice) genetic background CD8+ T cells are
thought to be more important in tumor promotion [13],
in the C3H background, CD4+ T cells are thought to be
tumor-promoting while CD8+ T cells are considered to be
protective [14]. Furthermore, cytokines such as interferon
c (IFN-c) and interleukin 12 (IL-12) have both been
shown to promote tumor development [15, 16], and sys-
temic administration of recombinant mouse IFN-c
resulted in increased numbers of papillomas [17]. In terms
of cytokine signaling, it has been shown that STAT3, a
signal transducer involved in regulation of various cyto-
kines (e.g., IL-5, IL-6, interferons, and leukemia inhibitory
factor), contributes to carcinogenesis [18]. In addition, the
transcription factor NF-jB, a downstream effector of
tumor necrosis factor a (TNF-a), has been suggested to
affect skin carcinogenesis [19]. While it is known that IL-4
also involves NF-jB (nuclear factor kappa light-chain
enhancer active in B cells) signaling, the effect of this type
2 helper T cells (TH2)-cytokine as well as the role of
(TH2)-dependent inflammatory responses, in general, in
skin carcinogenesis is incompletely understood. As TH2
cytokines have been associated with tissue responses like
wound healing and fibrosis, which are both implicated in
tumorigenesis, it is reasonable to assume that TH2 cyto-
kines may have an impact on skin tumor development.
Hence, we addressed the role of IL-4 and IL-13 in two-step
skin carcinogenesis in this study.
Material and Methods
Mice
IFN-c-deficient (IFN-c/) mice on the BALB/c back-
ground (F6) and wild-type BALB/c mice were purchased
from the Jackson Laboratories (Bar Harbor, ME). IL-4-
deficient (IL-4/), IL-4 receptor a chain-deficient
(IL-4Ra/) mice were generated with BALB/c embryonic
stem cells, recombination activating gene 2-deficient
(RAG2/) and RAG2//IL-4Ra/ double-deficient
mice were kindly provided by N. Noben-Trauth. IL-13-
deficient (IL-13/) mice were obtained from the MRC
Laboratory of Molecular Biology, Cambridge, and were
backcrossed to the BALB/c genetic background for six
generations. Heterozygous and homozygous gene-deficient
mice were generated by intercrossing gene-deficient mice
first with the respective control strain (e.g., BALB/c) and
afterward crossing the heterozygous F1 mice back to the
respective knockout mice. The offspring were genotyped
using the primers suggested by the Jackson Laboratories.
All mice were bred at the animal facility of the Max
Delbr€uck Center, Berlin.
Tumor induction
For induction of papillomas with DMBA/TPA a dorsal
area of skin of ~4 cm2 was shaved and 20 lg of DMBA
dissolved in 100 lL acetone was administered by a micro-
pipette. Starting 1 week later, 4 lg TPA dissolved in
100 lL acetone was applied on the same area of the skin
three times weekly for 20 weeks. The area was regularly
depilated and tumors were assessed two times weekly and
were defined as raised lesions of a minimum diameter of
1 mm that had been present for at least 1 week. Mice
were sacrificed if the tumor size reached ≥10 mm in
diameter or if tumors became invasive or ulcerated.
For induction of tumors with MCA, mice were injected
s.c. in the left abdominal region with 25 lg MCA in
0.1 mL of sesame oil. Tumor development was monitored
two to three times weekly. Mice with a tumor size of
≥10 mm in three perpendicular diameters were counted
as tumor positive.
Quantitative reverse transcriptase
polymerase chain reaction
Total RNA was isolated from 10 mm by 10 mm piece of
shaved back skin using TRIzol reagent (Ambion, Life
Technologies, Carlsbad, CA). Prior to reverse transcrip-
tion 1 lg of RNA was treated with RNase-free DNase I
(Thermo Scientific, Waltham, MA). Reverse transcription
was performed on 330 ng total RNA, random hexamers
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primed with SuperScript III First-Strand Synthesis Sys-
tem for reverse transcriptase polymerase chain reaction
(RT-PCR; Invitrogen [Carlsbad, CA], Life Technologies).
Quantitative PCR amplifications were performed from
50 ng of cDNA using Power SYBR Green Master Mix
(Applied Biosystems, Life Technologies) and Qiagen (Hil-
den, Germany) primer sets to murine GAPDH (Cat.#
PPM02946E), IL-4Ra (Cat.# PPM03025F), IL-4 (Cat.#
PPM03013F), IL-13 (Cat.# PPM03021B), IL-13Ra1
(Cat.# PPM03133F), IL-13Ra2 (Cat.# PPM03556C),
STAT6 (Cat.# PPM04646F), IFN-c (Cat.# PPM03121A),
IFN-cR1 (Cat.# PPM03134F). Amplifications were per-
formed on StepOne Real-Time PCR Instrument (Applied
Biosystems, Foster City, CA) as follows: one cycle for
10 min at 95°C, 40 cycles at 95°C for 15 sec, annealing
60°C for 1 min, and an extension of 90 sec at 72°C.
Cytometric bead array for serum cytokine
analysis
Blood samples were allowed to agglutinate followed by
two consecutive centrifugations (20,000g, 10 min, 4°C).
Supernatant was transferred into a fresh tube after each
centrifugation. Serum samples were aliquoted and stored
at 20°C. Aliquots were used only once to determine
serum levels of cytokines. Thirty microliters of serum was
analyzed using the cytometric bead array from Bender
Medsystems (eBioscience, San Diego, CA) according to
the manufacturer’s instructions. From this sample, the
levels of the following 10 cytokines were determined using
the TH1/TH2 10-plex kit (respective detection limits): IL-
1a (15.7 pg/mL), IL-2 (8.8 pg/mL), IL-4 (0.7 pg/mL),
IL-5 (4.0 pg/mL), IL-6 (2.2 pg/mL), IL-10 (5.4 pg/mL),
IL-17 (2.4 pg/mL), IFN-c (6.5 pg/mL), TNF-a (2.1 pg/
mL), and granulocyte macrophage colony stimulating fac-
tor (GM-CSF) (10.9 pg/mL). Flow cytometric analysis of
samples was performed on a BD FACS Calibur and data
were analyzed using the Bender Medsystems software.
Ethics statement
Animal experiments were performed with approval of the
Landesamt f€ur Gesundheit und Soziales, Berlin, Germany.
Results
TPA treatment enhances local IL-4Ra, IL-13,
IL-4, and IL-13Ra1 mRNA expression in the
skin and enhances systemic levels of IL-5
and IL-6
TPA application upregulates the IL-4 receptor alpha chain
(IL-4Ra) expression in the skin of NMRI (inbred strain
of mice) mice [20]. However, genetic background strongly
affects carcinogenesis [10] and also influences whether
inflammatory responses are dominated by either IL-4 or
IFN-c [21]. To study the role of IL-4 and IL-13 in skin
carcinogenesis, we used the BALB/c genetic background,
which tends to respond predominantly with an IL-4 dri-
ven inflammatory response. First, we tested whether IL-
4Ra or other TH2-related genes (IL-4, IL-13, and IL-13
receptors) or alternatively, some TH1-related genes (IFN-
c and IFN-cR1), as well as TNF-a are upregulated in the
skin of BALB/c mice upon TPA administration. To this
end, we applied 4 lg TPA dissolved in acetone to a
(shaved) dorsal skin area four times on consecutive days.
Two hours or 24 h after the last treatment the skin was
excised, RNA was extracted, transcribed into cDNA and
used for quantitative PCR analysis. As shown in
Figure 1A–H, IL-4Ra, IL-13, IL-4, and IL-13Ra1 were all
upregulated upon TPA treatment. Importantly, upregula-
tion of IL-4Ra and IL-13 occurred already after 2 h,
whereas significant changes in the expression levels of IL-
4 and IL-13Ra1 could be detected only at a later time
point. TNF-a was also upregulated, which is in line with
earlier published data on the role of TNF-a in this skin
carcinogenesis model [22–25].
In parallel to investigation of the local inflammation
induced by TPA (RNA expression analysis of skin tissues),
we assessed the systemic cytokine response in TPA-treated
mice 6 h after TPA treatment by analyzing serum levels
of 10 different cytokines: IL-1a, IL-2, IL-4, IL-5, IL-6,
IFN-c, IL-10, IL-17, TNF-a, and GM-CSF (using a cyto-
metric bead array). As shown in Figure 2A and B, we
detected an increase in serum cytokine levels after TPA
exposure for IL-6 (four of four mice; Fig. 2A) and IL-5
(three of four mice; Fig. 2B). For all other cytokines,
there was no detectable increase in the serum. There was
also no detectable increase in serum cytokine levels in the
untreated group or in response to acetone treatment (data
not shown).
Enhanced papilloma formation in
IL-4Ra/ mice
Because IL-4 and IL-4Ra were locally upregulated upon
TPA treatment, we next addressed the role of IL-4 and
the IL-4Ra chain in two-step carcinogenesis. Furthermore,
as IL-4 and IFN-c often counter regulate each other, we
also included analysis of IFN-c in the experiments. All of
our experiments were carried out using true littermate
control mice, because it has been reported that environ-
mental factors such as transport of mice, subtle strain-
specific alterations in host inflammatory responsiveness,
or breeding-colony-dependent differences in commensal
microflora may affect carcinogenesis [26–30]. Thus, we
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Figure 1. TPA treatment enhances mRNA levels of IL-4Ra, IL-13, IL-4, and IL-13Ra1. Skin of BALB/c mice (three to six females) was shaved on
day 0 and treated with 4 lg TPA on day 1, 3, 5, and 7 of the experiment. The area treated was excised on day 7 either at 2 h or at 24 h after
the last treatment. RNA was extracted and reverse transcribed to cDNA for quantitative real-time PCR analysis of IL-4Ra, IL-13, IL-4, IL-13Ra1, IL-
13Ra2, TNF-a, IFN-c, and IFN-cR1. Relative expression of target genes was calculated by normalization to GAPDH expression. Data presented as %
relative expression of the mean in the control acetone group. Statistical significance between groups, indicated by * (P ≤ 0.05), was calculated
using Kruskal–Wallis test. No significant difference was detected for IL-13Ra2, IFN-c, and IFN-cR1. Filled circles: mice treated with solvent only,
skin taken 24 h after last treatment; filled squares: mice treated with TPA in solvent, skin taken 2 h after last treatment; filled triangles: mice
treated with TPA in solvent, skin taken 24 h after last treatment. Each symbol represents one animal. Above each panel the respective cytokine/
receptor for which expression analysis was performed is indicated.
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performed a standard DMBA/TPA experiment [4] by
applying 20 lg DMBA and subsequently treating IL-4+/,
IL-4/, IL-4Ra+/, IL-4Ra/, IFN-c+/, and IFN-c/
mice for 20 weeks with TPA (4 lg three times weekly).
As shown in Figure 3A, the incidence of papillomas was
increased in IL-4Ra/ mice when compared to littermate
control IL-4Ra+/ mice and to all other experimental
groups. Neither deficiency in IL-4 (Fig. 3B) nor in IFN-c
(Fig. 3C) enhanced papilloma formation when compared
to heterozygous littermate control mice. A second inde-
pendent experiment comparing IL-4Ra/, IL-4/,
IFN-c/, and wild-type BALB/c mice showed the same
result, namely an increased papilloma incidence in
IL-4Ra/ mice (data not shown).
P = 0,0265P = 0,0294
IL-6 IL-5
A B
Figure 2. TPA treatment enhances systemic levels of IL-6 and IL-5. BALB/c mice were treated with 4 lg TPA dissolved in 100 lL acetone once.
Blood samples were taken and serum prepared either directly after treatment (0 h) or 6 h after treatment. Cytokine serum levels were
determined using a multiplex cytometric bead array. Shown are the total serum levels. Each symbol represents one animal. The respective
treatment is indicated below the diagram. Statistical significance, indicated by * (P ≤ 0.05), was calculated using Mann–Whitney U test (two-
tailed, using Gaussian approximation). Above each of the two panels the respective cytokine for which serum analysis was performed is indicated.
A
C
B
Figure 3. DMBA/TPA treatment enhances papilloma formation in IL-4Ra/ mice. Female mice were treated with 20 lg of DMBA. Seven days
later, mice were treated with 4 lg of TPA twice a week for 20 weeks. The development of skin papillomas is shown as mean per group (SD);
numbers in parentheses indicate group size. (A) IL-4/, IL-4+/; (B) IL-4Ra/, IL-4Ra+/; and (C) IFN-c/, IFN-c+/ mice. Statistical significance,
indicated by * (P ≤ 0.05), was calculated using Mann–Whitney U test (two-tailed, using Gaussian approximation).
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Next, we examined if absence of T cells or B cells
affected papilloma incidence with regard to the presence of
IL-4Ra. To this end, we compared papilloma incidence
between RAG2//IL-4Ra/ double-knockout mice and
RAG2//IL-4Ra+/ mice (Fig. 4A) as well as papil-
loma incidence between RAG2//IL-4Ra/ mice and
RAG2+/+/IL-4Ra/ mice (Fig. 4B) after DMBA/TPA
treatment. This experiment showed that even in the
absence of T cells or B cells, the difference in papilloma
incidence between IL-4Ra-deficient and IL-4Ra-competent
animals was retained although differences were less pro-
nounced. This suggested that T cells and B cells were not
the source of the protective cytokine nor was signaling in
T cells or B cells necessary for the protective effect.
While IL-13−/− mice show enhanced
papilloma development after DMBA/TPA
carcinogenesis, tumor incidence is unaltered
in IL-13−/− mice as compared to IL-13+/− after
MCA carcinogenesis
Because we detected an increase in papilloma incidence in
IL-4Ra/ compared to IL-4/ mice (Fig. 3), we rea-
soned that IL-13 as the second ligand for IL-4Ra might
have been responsible for this difference. Therefore, we
performed a two-step skin carcinogenesis experiment in
IL-13/ mice and heterozygous IL-13+/ littermates
(Fig. 5A) as well as homozygous IL-13+/+ mice (Fig. 5B)
using the same protocol as mentioned above. As shown
in Figure 5A and B and Figure S1, a similar, perhaps less
pronounced increase in papilloma incidence was observed
for IL-13/ mice as had been observed for IL-4Ra/
mice, suggesting that IL-13 signaling via IL-4Ra is respon-
sible for the protective effect.
Previously, we had shown that IL-4 as well as B cells
promote MCA carcinogenesis [26]. Because we found that
IL-13 is protective in DMBA/TPA carcinogenesis, we
wanted to know if IL-13 would influence MCA carcino-
genesis. Therefore, we injected IL-13/ and IL-13+/
mice backcrossed to the BALB/c genetic background with
25 lg of MCA. However, as shown in Figure 5C, there
was no difference in tumor induction or latency (time to
first tumor appearance) between IL-13+/ and IL-13/
mice.
Discussion
Various immunological factors have been previously
identified that may affect two-step carcinogenesis [9, 11,
13–18, 22–25, 31]. However, it still remains unclear how
exactly the inflammatory responses orchestrate tumor
development in this carcinogenesis protocol. In particular,
it was not known whether IL-4 or IL-13 affect DMBA/
TPA carcinogenesis. In this study, we addressed this ques-
tion and found that IL-4Ra and IL-13 but not IL-4 affects
two-step skin carcinogenesis.
Considering that IL-4/IL-13 and IFN-c/IL-12 counter
regulate each other, our finding that IL-13 is protective is
in line with the previous observation that IFN-c and IL-12
can be tumor-promoting in DMBA/TPA carcinogenesis
[15–17]. IFN-c has been shown to be tumor-promoting in
DMBA/TPA skin carcinogenesis in the majority of studies
that have analyzed the role of IFN-c [14–16, 32, 33]. How-
ever, one study reported a protective effect of IFN-c that
involved injection of plasmid DNA encoding IFN-c into
the tail vein of mice [32]. It remains unclear why IFN-c is
tumor-promoting in most DMBA/TPA carcinogenesis
studies but not in this study that used mice of the BALB/c
A B
Figure 4. Mice lacking IL-4Ra expression also show an enhanced papilloma incidence in the absence of T cells and B cells. RAG2//IL-4Ra/
mice and RAG2//IL-4Ra+/ mice (A) as well as RAG2//IL-4Ra/ mice and RAG2+/+/IL-4Ra/ mice (B) were treated with 20 lg of DMBA.
Starting day 7, mice were treated with 4 lg of TPA (twice a week) for 20 weeks. Development of skin papillomas is depicted as mean per group
(SD); numbers in parentheses indicate group size. Statistical significance, indicated by * (P ≤ 0.05), was calculated using Mann–Whitney U test
(two-tailed, using Gaussian approximation). (B) These mice were not true control littermates, but were derived from the same breeding colonies
kept in the same room with open cages. At week 16 and 18, three RAG2+/+/IL-4Ra/animals and six RAG2//IL-4Ra/ were taken out of the
experiment because of local irritation or damage to the skin after depilation.
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background. This may be due to the fact that BALB/c mice
show an immune response that is dominated by IL-4 and
do not develop a strong IFN-c response, while other
strains such as C57BL/6 mice show an IFN-c-dominated
immune response [21]. This assumption is supported by
the fact that we did not observe IFN-c RNA upregulation
after TPA application to the skin of BALB/c mice.
The exact target cell that mediates the tumor protec-
tive effect upon IL-13 signaling via the IL-4Ra has
yet to be defined. The fact that RAG2//IL-4Ra/
double-knockout mice and RAG2+/+/IL-4Ra/ both
showed increased papilloma incidence suggests that IL-
13 signaling neither in T cells, nor in B cells was the
main reason for enhanced papilloma incidence. Also,
the source of the protective cytokine IL-13 in our
experiments is not clear. However, it is unlikely that T
helper cells provide IL-13 upon TPA stimulation, as
studies analyzing the role of T helper cells in two-step
carcinogenesis have shown that they are tumor-promoting
rather than protective [14]. We consider it more likely
that other innate immune cells found in the skin are
the source of the protective IL-13 (such as dendritic
cells [34], mast cells [35], or eosinophils [36]).
Recently, a new cell type involved in mediating TH2-
cytokine-dependent skin inflammation has been identified
both in humans and in mice [37]. These cells belong to
group 2 innate lymphoid cells (ILC2), which produce
high levels of IL-13 and IL-5 [37, 38]. This is in line with
our observation that IL-13 is upregulated locally and that
IL-5 is increased systemically after TPA treatment of the
skin of BALB/c mice.
The contribution of cytokines to inflammation-induced
cancer is complex and may not only depend on the genetic
background of the mice but also on the target organ for a
particular carcinogen used. One such example highlighting
the importance of considering the target organ is provided
in an earlier study with chemically induced colitis-associ-
ated cancer using mice of the BALB/c genetic background.
In that study, the IL-4Ra signaling contributed to tumor
formation rather than to being protective against tumors
[39]. The outcome of carcinogenesis experiments may also
be affected by environmental factors such as the composi-
tion of the microbial commensals [40]. Many environmen-
tal factors such as transport of mice, subtle strain-specific
alterations in host inflammatory responsiveness, or breed-
ing-colony-dependent differences in commensal microflora
A B
C
Figure 5. IL-13/ mice show enhanced papilloma development after DMBA/TPA carcinogenesis but unaltered tumor incidence after MCA
carcinogenesis. (A) Enhanced papilloma formation in IL-13/ mice after DMBA/TPA treatment. Female mice (IL-13/; IL-13+/) were treated with
20 lg of DMBA. Starting day 7, the mice were treated with 4 lg of TPA (twice a week) for 20 weeks. Development of skin papillomas is
depicted as mean per group (SD); numbers in parentheses indicate group size. Exemplary photographs documenting papilloma incidence at
week 10 are shown in the Figure S1. (B) DMBA/TPA experiment as shown in (A) but using homozygous IL-13/ and IL-13+/+ (non littermates).
Statistical significance indicated by * (P ≤ 0.05) was calculated using Mann–Whitney U test (two-tailed, using Gaussian approximation). (C) No
difference in tumor incidence or latency between IL-13/ and IL-13+/ mice after MCA-carcinogenesis. IL-13/ (squares) and control littermates
IL-13+/ (diamonds) were injected with 25 lg MCA s.c., and tumor development was observed. Numbers in parentheses indicate group size.
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[41] may affect carcinogenesis [26, 27]. Potentially, differ-
ences in microbiota of the skin may also affect carcinogene-
sis, as it was reported that skin resident commensals can
strongly influence the local inflammatory milieu [28].
Commensals have also been shown to affect carcinogenesis
in a DMBA-driven liver tumor model [29] as well as in
another liver tumorigenesis model using diethylnitros-
amine and CCl4 [40].
One way to minimize differences in commensals would
be to use control littermates [41]. We had found previ-
ously that the use of littermate control mice is essential to
avoid misinterpretation of MCA carcinogenesis experi-
ments [26, 27, 30]. However, even when using littermate
controls, one cannot exclude that subtle (e.g., develop-
mental) differences other than those directly linked to the
gene defect may influence the phenotype of the mice. For
example, we observed that several transgenic immunodefi-
cient mice (including IFN-c/ or IL-4/ mice) had
slightly elevated serum levels for other cytokines than
those that were genetically ablated in the respective mouse
line, suggesting an altered baseline inflammatory respon-
siveness in these transgenic breeding colonies [27].
The systemic cytokine response after TPA application,
judging by serum cytokine titers, showed upregulation of
IL-5 as the only TH2 cytokine; other inflammatory cyto-
kines that were elevated were IL-6 and TNF-a. However,
neither IFN-c nor IL-4 titers were elevated. Nevertheless,
IFN-c and IL-4 are constitutively present in untreated
mice at very low levels and detectable only by the most
sensitive assays [42]. Interestingly, the role of inflamma-
tion appears to differ between DMBA/TPA- and MCA-
induced tumor development. For example, IL-4 enhances
MCA carcinogenesis [26], but here we show that it plays
no role in DMBA/TPA carcinogenesis. On the other hand,
IL-13 does not affect MCA carcinogenesis but is protec-
tive in DMBA/TPA carcinogenesis. Similarly, the presence
of TNF-a enhanced tumor development after the two-step
carcinogenesis with either DMBA/TPA [22] or with
DMBA, followed by tumor promotion with okadaic acid
[25]. However, TNF-a did not affect MCA-induced
tumor development [26].
The role of ab-T cell-induced inflammation differs for
both carcinogenesis protocols. While the presence of CD8+
T cells enhanced DMBA/TPA-induced carcinogenesis [13],
T-cell-deficient mice (Nude or RAG1/) revealed almost
none [30] or only a slightly enhanced susceptibility to MCA
[43]. Of note is that in the absence of inflammation, T cells
play no protective role by recognizing spontaneously
mutated proteins, because a recent study using mutagenesis
via a retrotransposition has shown that the adaptive
immune system does not suppress spontaneously develop-
ing tumors [44]. The differences observed in the inflamma-
tory response between these two models of chemical
carcinogenesis (DMBA/TPA versus MCA) are supported by
the observation that some mouse strains are relatively sus-
ceptible to DMBA/TPA but resistant to MCA [3, 45] (such
as the 129/Sv, which respond with a high level of inflamma-
tion). In fact, IFN-cR1/ mice on the 129/Sv genetic back-
ground were more resistant to MCA than IFN-cR1+/+ mice
on the C57BL/6 genetic background [45].
It seems that there is a marked difference between the
type of inflammation that promotes MCA carcinogenesis
versus that which promotes DMBA/TPA carcinogenesis.
Both anti-tumorigenic (IFN-c-mediated) and protumori-
genic (IL-4-mediated) inflammatory responses appear to
be involved in MCA-induced carcinogenesis. The role of
IFN-c responses for DMBA/TPA may be strain depen-
dent, because IFN-c is tumor-promoting in 129/Sv mice
[16, 17] but plays no role in BALB/c mice. However, IL-
13-driven immune responses are protective in DMBA/
TPA carcinogenesis, while they do not affect MCA carci-
nogenesis. Involvement of IL-4Ra in DMBA/TPA carcino-
genesis might have been anticipated by the observation
that TPA application upregulates the IL-4Ra expression
in the skin of NMRI mice [20]. We now confirmed this
observation for the BALB/c genetic background and,
moreover, found that IL-13Ra1 and IL-4 are both upreg-
ulated in the skin after TPA administration.
However, upregulation of IL-4 expression in the skin
after TPA application seems less relevant, as IL-4-deficient
mice showed the same incidence in papilloma develop-
ment as IL-4-competent heterozygous littermate controls.
We cannot formally exclude a gene dosage effect in het-
erozygous mice; wild-type (homozygous) gene levels IL-4
theoretically could influence carcinogenesis. However, in a
direct comparison of heterozygous mice, the effects of IL-
13 on carcinogenesis are clearly more important than
those of IL-4. Our observation that IL-13 is more impor-
tant than IL-4 in cutaneous inflammatory responses is in
line with earlier studies [46, 47] showing that cutaneous
responses are independent of IL-4 but instead depend on
IL-13 in a model of atopic inflammation in the skin. One
possible explanation can be due to the role of ILC2 that
mediate TH2-cytokine-dependent inflammatory responses
and serve as the main source of IL-13 in the skin [37, 38].
Furthermore, IL-4 and IL-13 may differentially regulate
signaling in target cells by employing distinct JAK/STAT-
mediated signaling pathways downstream of IL-13 and
IL-4 receptor complexes, resulting in differential inflam-
matory responses. A recent study demonstrates that IL-4
orchestrates downstream signaling via the IL-4Ra/JAK1/
STAT3/STAT6 axis, whereas IL-13 utilizes both IL-4Ra/
JAK2/STAT3 and IL-13Ra1/Tyk2/STAT1/STAT6 signaling
cascades to regulate expression of the target genes [48].
These results support our data and suggest that IL-13
may have unique effector functions in two-step skin
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carcinogenesis model, which differ from those of IL-4.
Taken together, a new perspective on the differential regu-
lation of IL-4/IL-13-mediated inflammation and the path-
ways previously thought to be similar should be further
investigated.
Acknowledgments
The authors thank Christian Friese and Doreen Vorpagel
for technical assistance. They also thank Maya Schreiber
and G. Heiden for critically reading the manuscript and
Andrew McKenzie for providing the IL-13/mice.
Conflict of Interest
None declared.
References
1. Yamagiva, K., and K. Ichikawa. 1918. Experimental study
of the pathogenesis of carcinoma. J. Cancer Res. 3:1–29.
2. Berenblum, I., and P. Shubik. 1947. The role of croton oil
applications, associated with a single painting of a
carcinogen, in tumour induction of the mouse’s skin. Br. J.
Cancer 1:379–382.
3. DiGiovanni, J. 1992. Multistage carcinogenesis in mouse
skin. Pharmacol. Ther. 54:63–128.
4. Abel, E. L., J. M. Angel, K. Kiguchi, and J. DiGiovanni.
2009. Multi-stage chemical carcinogenesis in mouse skin:
fundamentals and applications. Nat. Protoc. 4:1350–1362.
5. Deelman, H. T., and J. P. van Erp. 1926. Beobachtungen
an experimentellem tumorwachstum. €Uber den
zusammenhang zwischen regeneration und tumorbildung.
Z. Krebsforsch. 24:86–98.
6. Tannenbaum, A. 1942. The genesis and growth of tumors.
III. Effects of a high-fat diet. Cancer Res. 2:468–475.
7. Tannenbaum, A. 1942. The genesis and growth of tumors. II.
Effects of caloric restriction per se. Cancer Res. 2:460–467.
8. Arffmann, E., and N. Hjoorne. 1979. Influence of surface
lipids on skin carcinogenesis in rats. Acta Pathol.
Microbiol. Scand. A 87A:143–149.
9. Strawhecker, J. M., and J. C. Pelling. 1992. Inhibition of
mouse skin tumorigenesis by dexamethasone occurs
through a Ha-ras-independent mechanism. Carcinogenesis
13:2075–2080.
10. Sundberg, J. P., B. A. Sundberg, and W. G. Beamer. 1997.
Comparison of chemical carcinogen skin tumor induction
efficacy in inbred, mutant, and hybrid strains of mice:
morphologic variations of induced tumors and absence of
a papillomavirus cocarcinogen. Mol. Carcinog. 20:19–32.
11. Girardi, M., D. E. Oppenheim, C. R. Steele, J. M. Lewis,
E. Glusac, R. Filler, et al. 2001. Regulation of cutaneous
malignancy by gammadelta T cells. Science 294:605–609.
12. Girardi, M., E. Glusac, R. B. Filler, S. J. Roberts, I.
Propperova, J. Lewis, et al. 2003. The distinct
contributions of murine T cell receptor (TCR)
gammadelta+ and TCRalphabeta+ T cells to different
stages of chemically induced skin cancer. J. Exp. Med.
198:747–755.
13. Roberts, S. J., B. Y. Ng, R. B. Filler, J. Lewis, E. J. Glusac,
A. C. Hayday, et al. 2007. Characterizing
tumor-promoting T cells in chemically induced cutaneous
carcinogenesis. Proc. Natl. Acad. Sci. USA 104:6770–6775.
14. Yusuf, N., T. H. Nasti, S. K. Katiyar, M. K. Jacobs, M. D.
Seibert, A. C. Ginsburg, et al. 2008. Antagonistic roles of
CD4+ and CD8+ T-cells in 7,12-dimethylbenz(a)
anthracene cutaneous carcinogenesis. Cancer Res. 68:
3924–3930.
15. Sharma, S. D., S. M. Meeran, N. Katiyar, G. B. Tisdale,
N. Yusuf, H. Xu, et al. 2009. IL-12 deficiency suppresses
12-O-tetradecanoylphorbol-13-acetate-induced skin tumor
development in 7,12-dimethylbenz(a)anthracene-initiated
mouse skin through inhibition of inflammation.
Carcinogenesis 30:1970–1977.
16. Xiao, M., C. Wang, J. Zhang, Z. Li, X. Zhao, and Z. Qin.
2009. IFNgamma promotes papilloma development by
up-regulating Th17-associated inflammation. Cancer Res.
69:2010–2017.
17. Reiners, J. J., Jr., T. Rupp, A. Colby, A. R. Cantu, and
A. Pavone. 1989. Tumor copromoting activity of
gamma-interferon in the murine skin multistage
carcinogenesis model. Cancer Res. 49:1202–1206.
18. Kataoka, K., D. J. Kim, S. Carbajal, J. L. Clifford, and
J. DiGiovanni. 2008. Stage-specific disruption of Stat3
demonstrates a direct requirement during both the
initiation and promotion stages of mouse skin
tumorigenesis. Carcinogenesis 29:1108–1114.
19. Philip, M., D. A. Rowley, and H. Schreiber. 2004.
Inflammation as a tumor promoter in cancer induction.
Semin. Cancer Biol. 14:433–439.
20. Schlingemann, J., J. Hess, G. Wrobel, U. Breitenbach,
C. Gebhardt, P. Steinlein, et al. 2003. Profile of gene
expression induced by the tumour promotor TPA in
murine epithelial cells. Int. J. Cancer 104:699–708.
21. Heinzel, F. P., M. D. Sadick, B. J. Holaday, R. L. Coffman,
and R. M. Locksley. 1989. Reciprocal expression of
interferon gamma or interleukin 4 during the resolution
or progression of murine leishmaniasis. Evidence for
expansion of distinct helper T cell subsets. J. Exp. Med.
169:59–72.
22. Moore, R. J., D. M. Owens, G. Stamp, C. Arnott, F. Burke,
N. East, et al. 1999. Mice deficient in tumor necrosis
factor-alpha are resistant to skin carcinogenesis. Nat. Med.
5:828–831.
23. Rundhaug, J. E., I. Gimenez-Conti, M. C. Stern,
I. V. Budunova, K. Kiguchi, D. K. Bol, et al. 1997.
ª 2013 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 823
M. Rothe et al. IL-4 and IL-13 in DMBA/TPA Carcinogenesis
Changes in protein expression during multistage mouse
skin carcinogenesis. Mol. Carcinog. 20:125–136.
24. Schioppa, T., R. Moore, R. G. Thompson, E. C. Rosser,
H. Kulbe, S. Nedospasov, et al. 2011. B regulatory cells
and the tumor-promoting actions of TNF-alpha during
squamous carcinogenesis. Proc. Natl. Acad. Sci. USA
108:10662–10667.
25. Suganuma, M., S. Okabe, M. W. Marino, A. Sakai,
E. Sueoka, and H. Fujiki. 1999. Essential role of tumor
necrosis factor alpha (TNF-alpha) in tumor promotion as
revealed by TNF-alpha-deficient mice. Cancer Res.
59:4516–4518.
26. Kammertoens, T., Z. Qin, D. Briesemeister, A. Bendelac,
and T. Blankenstein. 2012. B-cells and IL-4 promote
methylcholanthrene-induced carcinogenesis but there is no
evidence for a role of T/NKT-cells and their effector
molecules (Fas-ligand, TNF-alpha, perforin). Int. J. Cancer
131:1499–1508.
27. Briesemeister, D., C. Friese, C. C. Isern, E. Dietz,
T. Blankenstein, C. Thoene-Reineke, et al. 2012.
Differences in serum cytokine levels between wild
type mice and mice with a targeted mutation suggests
necessity of using control littermates. Cytokine 60:
626–633.
28. Nakamura, Y., L. Franchi, N. Kambe, G. Meng, W.
Strober, and G. Nunez. 2012. Critical role for mast cells in
interleukin-1beta-driven skin inflammation associated with
an activating mutation in the nlrp3 protein. Immunity
37:85–95.
29. Grant, G. A., and F. J. Roe. 1969. Influence of germ-free
status on hepatoma induction by 7,12-dimethylbenz(a)
anthracene in C3H mice. Nature 222:1282–1283.
30. Qin, Z., and T. Blankenstein. 2004. A cancer
immunosurveillance controversy. Nat. Immunol. 5:3–4.
31. Girardi, M., D. Oppenheim, E. J. Glusac, R. Filler, A.
Balmain, R. E. Tigelaar, et al. 2004. Characterizing the
protective component of the alphabeta T cell response to
transplantable squamous cell carcinoma. J. Invest.
Dermatol. 122:699–706.
32. Ko, J. H., B. G. Jung, Y. S. Park, and B. J. Lee. 2011.
Inhibitory effects of interferon-gamma plasmid DNA on
DMBA-TPA induced mouse skin carcinogenesis. Cancer
Gene Ther. 18:646–654.
33. Wang, L., T. Yi, W. Zhang, D. M. Pardoll, and H. Yu. 2010.
IL-17 enhances tumor development in carcinogen-induced
skin cancer. Cancer Res. 70:10112–10120.
34. Bellinghausen, I., P. Brand, I. Bottcher, B. Klostermann,
J. Knop, and J. Saloga. 2003. Production of interleukin-13
by human dendritic cells after stimulation with protein
allergens is a key factor for induction of T helper 2
cytokines and is associated with activation of signal
transducer and activator of transcription-6. Immunology
108:167–176.
35. Burd, P. R., W. C. Thompson, E. E. Max, and F. C. Mills.
1995. Activated mast cells produce interleukin 13. J. Exp.
Med. 181:1373–1380.
36. Schmid-Grendelmeier, P., F. Altznauer, B. Fischer,
C. Bizer, A. Straumann, G. Menz, et al. 2002. Eosinophils
express functional IL-13 in eosinophilic inflammatory
diseases. J. Immunol. 169:1021–1027.
37. Kim, B. S., M. C. Siracusa, S. A. Saenz, M. Noti,
L. A. Monticelli, G. F. Sonnenberg, et al. 2013. TSLP elicits
IL-33-independent innate lymphoid cell responses to
promote skin inflammation. Sci. Transl. Med. 5:170ra16.
38. Roediger, B., R. Kyle, K. H. Yip, N. Sumaria, T. V. Guy,
B. S. Kim, et al. 2013. Cutaneous immunosurveillance and
regulation of inflammation by group 2 innate lymphoid
cells. Nat. Immunol. 14:564–573.
39. Koller, F. L., D. G. Hwang, E. A. Dozier, and B. Fingleton.
2010. Epithelial interleukin-4 receptor expression promotes
colon tumor growth. Carcinogenesis 31:1010–1017.
40. Dapito, D. H., A. Mencin, G. Y. Gwak, J. P. Pradere,
M. K. Jang, I. Mederacke, et al. 2012. Promotion of
hepatocellular carcinoma by the intestinal microbiota and
TLR4. Cancer Cell 21:504–516.
41. Ubeda, C., L. Lipuma, A. Gobourne, A. Viale, I. Leiner,
M. Equinda, et al. 2012. Familial transmission rather than
defective innate immunity shapes the distinct intestinal
microbiota of TLR-deficient mice. J. Exp. Med. 209:
1445–1456.
42. Finkelman, F. D., and S. C. Morris. 1999. Development of
an assay to measure in vivo cytokine production in the
mouse. Int. Immunol. 11:1811–1818.
43. O’Sullivan, T., R. Saddawi-Konefka, W. Vermi, C. M.
Koebel, C. Arthur, J. M. White, et al. 2012. Cancer
immunoediting by the innate immune system in the
absence of adaptive immunity. J. Exp. Med. 209:
1869–1882.
44. Rogers, L. M., A. K. Olivier, D. K. Meyerholz, and
A. J. Dupuy. 2013. Adaptive immunity does not strongly
suppress spontaneous tumors in a Sleeping Beauty model
of cancer. J. Immunol. 190:4393–4399.
45. Blankenstein, T., and Z. Qin. 2003. Chemical carcinogens
as foreign bodies and some pitfalls regarding cancer
immune surveillance. Adv. Cancer Res. 90:179–207.
46. Herrick, C. A., H. MacLeod, E. Glusac, R. E. Tigelaar, and
K. Bottomly. 2000. Th2 responses induced by epicutaneous
or inhalational protein exposure are differentially
dependent on IL-4. J. Clin. Invest. 105:765–775.
47. Herrick, C. A., L. Xu, A. N. McKenzie, R. E. Tigelaar, and
K. Bottomly. 2003. IL-13 is necessary, not simply
sufficient, for epicutaneously induced Th2 responses to
soluble protein antigen. J. Immunol. 170:2488–2495.
48. Bhattacharjee, A., M. Shukla, V. P. Yakubenko, A. Mulya,
S. Kundu, and M. K. Cathcart. 2013. IL-4 and IL-13
employ discrete signaling pathways for target gene
824 ª 2013 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
IL-4 and IL-13 in DMBA/TPA Carcinogenesis M. Rothe et al.
expression in alternatively activated monocytes/
macrophages. Free Radical Biol. Med. 54:1–16.
Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Figure S1. Exemplary pictures of papilloma incidence in
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